Bart Keymeulen

Bart Keymeulen

Auto-generated profile, based on publicly available information

Bart Keymeulen

Diabetes Research Center, Vrije Universiteit Brussel (VUB), Brussels, Belgium

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2005 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
BKBart Keymeulen
Bart Keymeulen
EVEvy Vandemeulebroucke
Evy Vandemeulebroucke
AZAnette G. Ziegler
Anette G. Ziegler
CMChantal Mathieu
Chantal Mathieu
LKLeonard Kaufman
Leonard Kaufman
LCLucienne Chatenoud
Lucienne Chatenoud
Type 1 diabetes mellitus is a T-cell–mediated autoimmune disease that leads to a major loss of insulin-secreting beta cells. The further decline of beta-cell function after clinical onset might be prevented by treatment with CD3 monoclonal antibodies, as suggested by the results of a phase 1 study. To provide proof of this therapeutic principle at the metabolic level, we initiated a phase 2 placebo-controlled trial with a humanized antibody, an aglycosylated human IgG1 antibody directed against CD3 (ChAglyCD3). In a multicenter study, 80 patients with new-onset type 1 diabetes were randomly assigned to receive placebo or ChAglyCD3 for six consecutive days. Patients were followed for 18 months, during which their daily insulin needs and residual beta-cell function were assessed according to glucose-clamp–induced C-peptide release before and after the administration of glucagon. At 6, 12, and 18 months, residual beta-cell function was better maintained with ChAglyCD3 than with placebo. The insulin dose increased in the placebo group but not in the ChAglyCD3 group. This effect of ChAglyCD3 was most pronounced among patients with initial residual beta-cell function at or above the 50th percentile of the 80 patients. In this subgroup, the mean insulin dose at 18 months was 0.22 IU per kilogram of body weight per day with ChAglyCD3, as compared with 0.61 IU per kilogram with placebo (P<0.001). In this subgroup, 12 of 16 patients who received ChAglyCD3 (75 percent) received minimal doses of insulin (≤0.25 IU per kilogram per day) as compared with none of the 21 patients who received placebo. Administration of ChAglyCD3 was associated with a moderate “flu-like” syndrome and transient symptoms of Epstein–Barr viral mononucleosis. Short-term treatment with CD3 antibody preserves residual beta-cell function for at least 18 months in patients with recent-onset type 1 diabetes.

1 November 2006 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
GHGary A. Herman
Gary A. Herman
ABArthur Bergman
Arthur Bergman
CSCatherine Stevens
Catherine Stevens
PKPaul Kotey
Paul Kotey
BYBingming Yi
Bingming Yi
JWJohn A. Wagner
John A. Wagner
Context: In response to a meal, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are released and modulate glycemic control. Normally these incretins are rapidly degraded by dipeptidyl peptidase-4 (DPP-4). DPP-4 inhibitors are a novel class of oral antihyperglycemic agents in development for the treatment of type 2 diabetes. The degree of DPP-4 inhibition and the level of active incretin augmentation required for glucose lowering efficacy after an oral glucose tolerance test (OGTT) were evaluated. Objective: The objective of the study was to examine the pharmacodynamics, pharmacokinetics, and tolerability of sitagliptin. Design: This was a randomized, double-blind, placebo-controlled, three-period, single-dose crossover study. Setting: The study was conducted at six investigational sites. Patients: The study population consisted of 58 patients with type 2 diabetes who were not on antihyperglycemic agents. Interventions: Interventions included sitagliptin 25 mg, sitagliptin 200 mg, or placebo. Main Outcome Measures: Measurements included plasma DPP-4 activity; post-OGTT glucose excursion; active and total incretin GIP levels; insulin, C-peptide, and glucagon concentrations; and sitagliptin pharmacokinetics. Results: Sitagliptin dose-dependently inhibited plasma DPP-4 activity over 24 h, enhanced active GLP-1 and GIP levels, increased insulin/C-peptide, decreased glucagon, and reduced glycemic excursion after OGTTs administered at 2 and 24 h after single oral 25- or 200-mg doses of sitagliptin. Sitagliptin was generally well tolerated, with no hypoglycemic events. Conclusions: In this study in patients with type 2 diabetes, near maximal glucose-lowering efficacy of sitagliptin after single oral doses was associated with inhibition of plasma DPP-4 activity of 80% or greater, corresponding to a plasma sitagliptin concentration of 100 nm or greater, and an augmentation of active GLP-1 and GIP levels of 2-fold or higher after an OGTT.

14 January 2010 in Diabetologia
Verified
Journal Article
Closed access
PDF file
BKB. Keymeulen
B. Keymeulen
MWM. Walter
M. Walter
CMC. Mathieu
C. Mathieu
LKL. Kaufman
L. Kaufman
FGF. Gorus
F. Gorus
DPD. Pipeleers
D. Pipeleers

12 May 2015 in Diabetes Care
Verified
Journal Article
Open access
PDF file
PCPratik Choudhary
Pratik Choudhary
MRMichael R. Rickels
Michael R. Rickels
PSPeter A. Senior
Peter A. Senior
MVMarie-Christine Vantyghem
Marie-Christine Vantyghem
PMPaola Maffi
Paola Maffi
BHBernhard J. Hering
Bernhard J. Hering
Problematic hypoglycemia, defined as two or more episodes per year of severe hypoglycemia or as one episode associated with impaired awareness of hypoglycemia, extreme glycemic lability, or major fear and maladaptive behavior, is a challenge, especially for patients with long-standing type 1 diabetes. Individualized therapy for such patients should include a composite target: optimal glucose control without problematic hypoglycemia. Therefore, we propose a tiered, four-stage algorithm based on evidence of efficacy given the limitations of educational, technological, and transplant interventions. All patients with problematic hypoglycemia should undergo structured or hypoglycemia-specific education programs (stage 1). Glycemic and hypoglycemia treatment targets should be individualized and reassessed every 3–6 months. If targets are not met, one diabetes technology—continuous subcutaneous insulin infusion or continuous glucose monitoring—should be added (stage 2). For patients with continued problematic hypoglycemia despite education (stage 1) and one diabetes technology (stage 2), sensor-augmented insulin pumps preferably with an automated low-glucose suspend feature and/or very frequent contact with a specialized hypoglycemia service can reduce hypoglycemia (stage 3). For patients whose problematic hypoglycemia persists, islet or pancreas transplant should be considered (stage 4). This algorithm provides an evidence-informed approach to resolving problematic hypoglycemia; it should be used as a guide, with individual patient circumstances directing suitability and acceptability to ensure the prudent use of technology and scarce transplant resources. Standardized reporting of hypoglycemia outcomes and inclusion of patients with problematic hypoglycemia in studies of new interventions may help to guide future therapeutic strategies.

26 April 2013 in Diabetologia
Verified
Journal Article
Closed access
PDF file
DJD. Jacobs-Tulleneers-Thevissen
D. Jacobs-Tulleneers-Thevissen
MCM. Chintinne
M. Chintinne
ZLZ. Ling
Z. Ling
PGP. Gillard
P. Gillard
LSL. Schoonjans
L. Schoonjans
DPD. Pipeleers
D. Pipeleers

31 March 2010 in Diabetes
Verified
Journal Article
Open access
JVJurjen H. Velthuis
Jurjen H. Velthuis
WUWendy W. Unger
Wendy W. Unger
JAJoana R.F. Abreu
Joana R.F. Abreu
GDGaby Duinkerken
Gaby Duinkerken
KFKees Franken
Kees Franken
BRBart Roep
Bart Roep
OBJECTIVE: Type 1 diabetes results from selective T-cell–mediated destruction of the insulin-producing β-cells in the pancreas. In this process, islet epitope–specific CD8+ T-cells play a pivotal role. Thus, monitoring of multiple islet–specific CD8+ T-cells may prove to be valuable for measuring disease activity, progression, and intervention. Yet, conventional detection techniques (ELISPOT and HLA tetramers) require many cells and are relatively insensitive.RESEARCH DESIGN AND METHODS: Here, we used a combinatorial quantum dot major histocompatibility complex multimer technique to simultaneously monitor the presence of HLA-A2 restricted insulin B10–18, prepro-insulin (PPI)15–24, islet antigen (IA)-2797–805, GAD65114–123, islet-specific glucose-6-phosphatase catalytic subunit–related protein (IGRP)265–273, and prepro islet amyloid polypeptide (ppIAPP)5–13–specific CD8+ T-cells in recent-onset diabetic patients, their siblings, healthy control subjects, and islet cell transplantation recipients.RESULTS: Using this kit, islet autoreactive CD8+ T-cells recognizing insulin B10–18, IA-2797–805, and IGRP265–273 were shown to be frequently detectable in recent-onset diabetic patients but rarely in healthy control subjects; PPI15–24 proved to be the most sensitive epitope. Applying the “Diab-Q-kit” to samples of islet cell transplantation recipients allowed detection of changes of autoreactive T-cell frequencies against multiple islet cell–derived epitopes that were associated with disease activity and correlated with clinical outcome.CONCLUSIONS: A kit was developed that allows simultaneous detection of CD8+ T-cells reactive to multiple HLA-A2–restricted β-cell epitopes requiring limited amounts of blood, without a need for in vitro culture, that is applicable on stored blood samples.